Sugammadex Causes C6 Glial Cell Death and Exacerbates Hydrogen Peroxide-Induced Oxidative Stress

Bilal Şahin; Sabahattin Karabulut

doi:10.7197/cmj.1069629

Araştırma Makalesi

Sugammadex Causes C6 Glial Cell Death and Exacerbates Hydrogen Peroxide-Induced Oxidative Stress

Yıl 2022, Cilt: 44 Sayı: 1, 22 - 27, 30.03.2022

Bilal Şahin , Sabahattin Karabulut

https://doi.org/10.7197/cmj.1069629

Cited By: 1

Öz

Objective: Sugammadex (SUG) quickly reverses steroidal neuromuscular blocking drugs after anesthesia. It has been reported that SUG has a toxic effect on neurons in primary culture. This study aims to examine the effect of SUG on glial cell viability, oxidative stress, and apoptosis in C6 glial cells after exposure to H2O2.
Method: In this study, C6 glioma cell line was used to study the effect of SUG on the glial cell in four cell groups. The control group was untreated. Cells in the H2O2group were treated with 0.5 mM H2O2 for 24 h. Cells in the SUG group were treated with 50 μg/mL SUG for 24 h. Cells in the SUG+ H2O2 group were pre-treated with 50 μg/mL of SUG for 1 h before 24-h exposure to 0.5 mM H2O2. Cell viability was evaluated using XTT assay. Total antioxidant status (TAS), total oxidant status (TOS), caspase-3, Bax, 8-hydroxy-2′ -deoxyguanosine (8-OHdG), and cleaved-PARP levels in the cells were measured by commercial kits.
Results: SUG significantly decreased the viability of C6 cells after H2O2-induced oxidative stress (p < 0.05). SUG pretreatment also raised TOS levels and led to increased Bax, Caspase-3, 8-OHdG, and cleaved PARP levels after H2O2-induced oxidative damage in C6 cells (p < 0.05).

Anahtar Kelimeler

suggammadex, cell death, C6 glioma

Teşekkür

We would like to thank the Sivas Cumhuriyet University, School of Medicine, CUTFAM Research Center, Sivas, Turkey, for providing the necessary facilities to conduct this study.

Kaynakça

1. Stäuble CG, Blobner M. The future of neuromuscular blocking agents. Curr Opin Anaesthesiol. 2020;33(4):490-498. doi:10.1097/ACO.0000000000000891
2. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111(1):120-128. doi:10.1213/ANE.0b013e3181da832d
3. Karalapillai D, Kaufman M, Weinberg L. Sugammadex. Crit Care Resusc. 2013;15(1):57-62.
4. Hawkins J, Khanna S, Argalious M. Sugammadex for Reversal of Neuromuscular Blockade: Uses and Limitations. Curr Pharm Des. 2019;25(19):2140-2148. doi:10.2174/1381612825666190704101145
5. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104(4):667-674. doi:10.1097/00000542-200604000-00009
6. de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007;107(2):239-244. doi:10.1097/01.anes.0000270722.95764.37
7. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007;106(5):935-943. doi:10.1097/01.anes.0000265152.78943.74
8. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017;8(8):CD012763. doi:10.1002/14651858.CD012763
9. Honing G, Martini CH, Bom A, et al. Safety of sugammadex for reversal of neuromuscular block. Expert Opin Drug Saf. 2019;18(10):883-891. doi:10.1080/14740338.2019.1649393
10. Kovac AL. Sugammadex: the first selective binding reversal agent for neuromuscular block. J Clin Anesth. 2009;21(6):444-453. doi:10.1016/j.jclinane.2009.05.002
11. Lazo Uslar C, Navarro Vives L, Miquel Marco S, Roger Reig A, Basagaña Torrento M. Sugammadex Induced Anaphylaxis: Two Case Reports [published online ahead of print, 2021 Jun 15]. J Investig Allergol Clin Immunol. 2021;0. doi:10.18176/jiaci.0719
12. Palanca JM, Aguirre-Rueda D, Granell MV, et al. Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures. Int J Med Sci. 2013;10(10):1278-1285. Published 2013 Aug 3. doi:10.7150/ijms.6254
13. Wu YC, Sonninen TM, Peltonen S, Koistinaho J, Lehtonen Š. Blood-Brain Barrier and Neurodegenerative Diseases-Modeling with iPSC-Derived Brain Cells. Int J Mol Sci. 2021;22(14):7710. Published 2021 Jul 19. doi:10.3390/ijms22147710
14. Chodobski A, Zink BJ, Szmydynger-Chodobska J. Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res. 2011;2(4):492-516. doi:10.1007/s12975-011-0125-x
15. Galea I. The blood-brain barrier in systemic infection and inflammation. Cell Mol Immunol. 2021;18(11):2489-2501. doi:10.1038/s41423-021-00757-x
16. Saunders NR, Knott GW, Dziegielewska KM. Barriers in the immature brain. Cell Mol Neurobiol. 2000;20(1):29-40. doi:10.1023/a:1006991809927
17. Erel, O. A Novel Automated Direct Measurement Method for Total Antioxidant Capacity Using a New Generation, More Stable ABTS Radical Cation. Clin. Biochem., 2004, 37(4), 277–85.
18. Erel, O. A New Automated Colorimetric Method for Measuring Total Oxidant Status. Clin. Biochem., 2005, 38(12), 1103–11.
19. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care. 2009;24(1):29-35. doi:10.1016/j.jcrc.2008.10.010
20. Jeyadoss J, Kuruppu P, Nanjappa N, Van Wijk R. Sugammadex hypersensitivity-a case of anaphylaxis. Anaesth Intensive Care. 2014;42(1):89-92. doi:10.1177/0310057X1404200115
21. Tauffenberger A, Magistretti PJ. Reactive Oxygen Species: Beyond Their Reactive Behavior. Neurochem Res. 2021;46(1):77-87. doi:10.1007/s11064-020-03208-7
22. Arslan B, Sahin T, Ozdogan H. Sugammadex and anaphylaxis: An analysis of 33 published cases. J Anaesthesiol Clin Pharmacol. 2021;37(2):153-159. doi:10.4103/joacp.JOACP_383_19

Yıl 2022, Cilt: 44 Sayı: 1, 22 - 27, 30.03.2022

Bilal Şahin , Sabahattin Karabulut

https://doi.org/10.7197/cmj.1069629

Cited By: 1

Öz

Kaynakça

1. Stäuble CG, Blobner M. The future of neuromuscular blocking agents. Curr Opin Anaesthesiol. 2020;33(4):490-498. doi:10.1097/ACO.0000000000000891
2. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111(1):120-128. doi:10.1213/ANE.0b013e3181da832d
3. Karalapillai D, Kaufman M, Weinberg L. Sugammadex. Crit Care Resusc. 2013;15(1):57-62.
4. Hawkins J, Khanna S, Argalious M. Sugammadex for Reversal of Neuromuscular Blockade: Uses and Limitations. Curr Pharm Des. 2019;25(19):2140-2148. doi:10.2174/1381612825666190704101145
5. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104(4):667-674. doi:10.1097/00000542-200604000-00009
6. de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007;107(2):239-244. doi:10.1097/01.anes.0000270722.95764.37
7. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007;106(5):935-943. doi:10.1097/01.anes.0000265152.78943.74
8. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017;8(8):CD012763. doi:10.1002/14651858.CD012763
9. Honing G, Martini CH, Bom A, et al. Safety of sugammadex for reversal of neuromuscular block. Expert Opin Drug Saf. 2019;18(10):883-891. doi:10.1080/14740338.2019.1649393
10. Kovac AL. Sugammadex: the first selective binding reversal agent for neuromuscular block. J Clin Anesth. 2009;21(6):444-453. doi:10.1016/j.jclinane.2009.05.002
11. Lazo Uslar C, Navarro Vives L, Miquel Marco S, Roger Reig A, Basagaña Torrento M. Sugammadex Induced Anaphylaxis: Two Case Reports [published online ahead of print, 2021 Jun 15]. J Investig Allergol Clin Immunol. 2021;0. doi:10.18176/jiaci.0719
12. Palanca JM, Aguirre-Rueda D, Granell MV, et al. Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures. Int J Med Sci. 2013;10(10):1278-1285. Published 2013 Aug 3. doi:10.7150/ijms.6254
13. Wu YC, Sonninen TM, Peltonen S, Koistinaho J, Lehtonen Š. Blood-Brain Barrier and Neurodegenerative Diseases-Modeling with iPSC-Derived Brain Cells. Int J Mol Sci. 2021;22(14):7710. Published 2021 Jul 19. doi:10.3390/ijms22147710
14. Chodobski A, Zink BJ, Szmydynger-Chodobska J. Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res. 2011;2(4):492-516. doi:10.1007/s12975-011-0125-x
15. Galea I. The blood-brain barrier in systemic infection and inflammation. Cell Mol Immunol. 2021;18(11):2489-2501. doi:10.1038/s41423-021-00757-x
16. Saunders NR, Knott GW, Dziegielewska KM. Barriers in the immature brain. Cell Mol Neurobiol. 2000;20(1):29-40. doi:10.1023/a:1006991809927
17. Erel, O. A Novel Automated Direct Measurement Method for Total Antioxidant Capacity Using a New Generation, More Stable ABTS Radical Cation. Clin. Biochem., 2004, 37(4), 277–85.
18. Erel, O. A New Automated Colorimetric Method for Measuring Total Oxidant Status. Clin. Biochem., 2005, 38(12), 1103–11.
19. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care. 2009;24(1):29-35. doi:10.1016/j.jcrc.2008.10.010
20. Jeyadoss J, Kuruppu P, Nanjappa N, Van Wijk R. Sugammadex hypersensitivity-a case of anaphylaxis. Anaesth Intensive Care. 2014;42(1):89-92. doi:10.1177/0310057X1404200115
21. Tauffenberger A, Magistretti PJ. Reactive Oxygen Species: Beyond Their Reactive Behavior. Neurochem Res. 2021;46(1):77-87. doi:10.1007/s11064-020-03208-7
22. Arslan B, Sahin T, Ozdogan H. Sugammadex and anaphylaxis: An analysis of 33 published cases. J Anaesthesiol Clin Pharmacol. 2021;37(2):153-159. doi:10.4103/joacp.JOACP_383_19

Toplam 22 adet kaynakça vardır.

Ayrıntılar

Birincil Dil	İngilizce
Konular	Sağlık Kurumları Yönetimi
Bölüm	Temel Tıp Bilimleri Araştırma Yazıları
Yazarlar	Bilal Şahin 0000-0002-4419-1385 Sabahattin Karabulut 0000-0002-3261-4125
Yayımlanma Tarihi	30 Mart 2022
Kabul Tarihi	23 Mart 2022
Yayımlandığı Sayı	Yıl 2022Cilt: 44 Sayı: 1

Kaynak Göster

AMA	Şahin B, Karabulut S. Sugammadex Causes C6 Glial Cell Death and Exacerbates Hydrogen Peroxide-Induced Oxidative Stress. CMJ. Mart 2022;44(1):22-27. doi:10.7197/cmj.1069629

Cumhuriyet Medical Journal

Sugammadex Causes C6 Glial Cell Death and Exacerbates Hydrogen Peroxide-Induced Oxidative Stress

Öz

Anahtar Kelimeler

Teşekkür

Kaynakça

Öz

Kaynakça

Ayrıntılar

Kaynak Göster

Cited By

The protective effect of venlafaxine on hydrogen peroxide-induced cytotoxicity in C6 glioma cells

Acta Medica Alanya

https://doi.org/10.30565/medalanya.1459206